Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of bortezomib and how well it works
in treating patients with malignant pleural mesothelioma.